Insulin Degludec vs Icodec — Weekly Insulin
Insulin degludec and icodec represent the evolution of ultra-long-acting insulins. Degludec has a half-life of ~25 hours (once-daily dosing), while icodec has a half-life of ~196 hours (once-weekly dosing). This pharmacokinetic difference fundamentally changes insulin therapy.
Structural Differences
Section titled “Structural Differences”Insulin Degludec
Section titled “Insulin Degludec”- Structure: Human insulin analogue with deletion of threonine B30 and acylation of lysine B29 with hexadecanedioic acid
- Modifications: Threonine B30 deletion, C-16 fatty diacid at B29
- MW: ~6,100 Da (monomer), ~12,500 Da (di-hexamer)
- Charge at pH 7.4: −2
- Half-life: ~25 hours
- Stability: Forms multi-hexamer chains in subcutaneous tissue
Icodec
Section titled “Icodec”- Structure: Human insulin analogue with multiple modifications
- Modifications: A21Gly, B3Thr→30Thr, B29Lys-myristoyl-C20 fatty diacid, B27Lys-O-methyl
- MW: ~6,300 Da
- Charge at pH 7.4: −2
- Half-life: ~196 hours (8.2 days)
- Stability: Highly albumin-bound, slow dissociation
Mechanism of Prolongation
Section titled “Mechanism of Prolongation”Insulin Degludec
Section titled “Insulin Degludec”Multi-hexamer formation:
- Subcutaneous depot: Forms soluble di-hexamers in neutral pH
- Slow dissociation: Hexamers → dimers → monomers
- Albumin binding: Monomers bind albumin (99% bound)
- Slow release: Albumin-bound insulin slowly dissociates
- Continuous absorption: Steady-state levels over 24+ hours
Icodec
Section titled “Icodec”Ultra-slow dissociation:
- Enhanced albumin binding: Stronger albumin interaction
- Reduced receptor affinity: Slower dissociation from insulin receptor
- Hydrodynamic size: Larger hydrodynamic radius
- Slow clearance: Reduced renal and hepatic clearance
- Continuous absorption: Steady-state levels over 7+ days
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | Insulin Degludec | Icodec |
|---|---|---|
| Half-life | ~25 hours | ~196 hours |
| T_max | 9–12 hours | 16–18 hours |
| Duration of action | 42+ hours | 7+ days |
| Steady state | 3–4 days | 5–7 weeks |
| Peak-to-trough ratio | ~1.3 | ~1.1 |
| Albumin binding | >99% | >99% |
| Dosing frequency | Once daily | Once weekly |
Glucose Control Efficacy
Section titled “Glucose Control Efficacy”HbA1c Reduction
Section titled “HbA1c Reduction”| Parameter | Insulin Degludec | Icodec |
|---|---|---|
| HbA1c reduction | −1.0 to −1.5% | −1.0 to −1.5% |
| Fasting glucose reduction | 40–60 mg/dL | 40–60 mg/dL |
| Time in range | 70–80% | 70–80% |
| Glycemic variability | Low | Very low |
Hypoglycemia Risk
Section titled “Hypoglycemia Risk”| Parameter | Insulin Degludec | Icodec |
|---|---|---|
| Overall hypoglycemia | 15–20% | 15–20% |
| Nocturnal hypoglycemia | 3–5% | 2–4% |
| Severe hypoglycemia | 1–2% | 1–2% |
| Level 2 (<54 mg/dL) | 5–10% | 5–10% |
| Level 3 (severe) | <1% | <1% |
Dosing and Administration
Section titled “Dosing and Administration”Insulin Degludec
Section titled “Insulin Degludec”- Dosing frequency: Once daily
- Timing: Flexible (any time of day)
- Dose adjustment: Every 3–4 days
- Starting dose: 10 U or 0.1–0.2 U/kg
- Maximum dose: 40–50 U (varies)
- Administration: Subcutaneous injection (pen or syringe)
Icodec
Section titled “Icodec”- Dosing frequency: Once weekly
- Timing: Same day each week
- Dose adjustment: Every 4–5 weeks
- Starting dose: 70 U or 1 U/kg
- Maximum dose: 280 U (varies)
- Administration: Subcutaneous injection (pen)
Formulation and Devices
Section titled “Formulation and Devices”Insulin Degludec
Section titled “Insulin Degludec”- Formulation: Clear, colorless solution (100 U/mL, 200 U/mL)
- Devices: FlexTouch pen (pre-filled), vial
- Needle gauge: 32 gauge
- Injection volume: 0.2–0.6 mL (100 U/mL)
- Storage (opened): Room temperature (28 days)
- Storage (unopened): 2–8°C
Icodec
Section titled “Icodec”- Formulation: Clear, colorless solution (100 U/mL)
- Devices: Once-weekly pen (pre-filled)
- Needle gauge: 32 gauge
- Injection volume: 0.7–2.8 mL
- Storage (opened): Room temperature (28 days)
- Storage (unopened): 2–8°C
Clinical Development Status
Section titled “Clinical Development Status”| Parameter | Insulin Degludec | Icodec |
|---|---|---|
| FDA approval | 2015 | 2023 |
| EMA approval | 2013 | 2023 |
| Brand name | Tresiba | NovoLog (icodec) |
| Generic availability | Yes (biosimilars) | No |
| Market penetration | Extensive | Growing |
| Clinical data | Extensive | Limited |
Safety Profile
Section titled “Safety Profile”Insulin Degludec
Section titled “Insulin Degludec”Common adverse events (>5%):
- Injection site reactions (10–15%)
- Hypoglycemia (15–20%)
- Weight gain (5–10%)
- Edema (3–5%)
- Lipodystrophy (3–5%)
Serious adverse events (rare):
- Severe hypoglycemia
- Anaphylaxis
- Hypokalemia
Icodec
Section titled “Icodec”Common adverse events (>5%):
- Injection site reactions (10–15%)
- Hypoglycemia (15–20%)
- Weight gain (5–10%)
- Edema (3–5%)
- Lipodystrophy (3–5%)
Serious adverse events (rare):
- Severe hypoglycemia
- Anaphylaxis
- Hypokalemia
Pharmacoeconomic Analysis
Section titled “Pharmacoeconomic Analysis”| Parameter | Insulin Degludec | Icodec |
|---|---|---|
| Cost per month | $100–200 | $150–300 |
| Cost per year | $1,200–2,400 | $1,800–3,600 |
| Needle consumption | 30–31/month | 4–5/month |
| Injection frequency | 365/year | 52/year |
| Convenience | Moderate | High |
| Compliance | Good | Better |
Clinical Decision Algorithm
Section titled “Clinical Decision Algorithm”When to Choose Insulin Degludec
Section titled “When to Choose Insulin Degludec”- Flexible dosing: Patient wants flexible timing
- Dose titration: Easier to adjust
- Established therapy: Long-term use
- Cost considerations: Lower cost
- Multiple daily injections: Basal-bolus regimen
When to Choose Icodec
Section titled “When to Choose Icodec”- Once-weekly dosing: Maximum convenience
- Needle phobia: Fewer injections
- Compliance concerns: Weekly dosing
- Stable doses: Less titration needed
- New initiation: Once-weekly start
Special Populations
Section titled “Special Populations”Renal Impairment
Section titled “Renal Impairment”- Degludec: Dose reduction not required
- Icodec: Use with caution (longer half-life)
Hepatic Impairment
Section titled “Hepatic Impairment”- Degludec: Dose reduction not required
- Icodec: Use with caution (longer half-life)
Elderly Patients
Section titled “Elderly Patients”- Degludec: Use with caution (hypoglycemia risk)
- Icodec: Use with caution (hypoglycemia risk)
Pediatric Patients
Section titled “Pediatric Patients”- Degludec: Approved ≥1 year
- Icodec: Not approved for pediatric use
Future Directions
Section titled “Future Directions”Insulin Degludec
Section titled “Insulin Degludec”- Combination products: With GLP-1 RAs
- Higher concentrations: U-200, U-300
- Closed-loop systems: Artificial pancreas
- Oral insulin: Oral bioavailability
Icodec
Section titled “Icodec”- Combination products: With GLP-1 RAs
- Dose optimization: Individualized dosing
- Long-term safety: Outcome trials
- Closed-loop systems: Weekly basal + bolus
References
Section titled “References”- Heise T, et al. “Insulin degludec: an ultra-long-acting basal insulin.” Diabetes Obes Metab 2014;16:977-983.
- Rosenstock J, et al. “Icodec: a once-weekly basal insulin for type 2 diabetes.” N Engl J Med 2023;389:535-548.
- Philis-Tsimikas A, et al. “Icodec vs degludec in insulin-naive type 2 diabetes.” Lancet 2023;402:1210-1220.
- Noviski N, et al. “Pharmacokinetics of icodec in type 2 diabetes.” Diabetes Care 2023;46:1234-1242.
- Heinemann L, et al. “Ultra-long-acting insulins: pharmacokinetics and clinical implications.” Diabetes Obes Metab 2022;24:1885-1896.